Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages 4040-4050

  Ayala Ramirez, Montserrat ^a   Chougnet, Cecile N ^b   Habra, Mouhammed Amir ^a   Palmer, J Lynn ^a   Leboulleux, Sophie ^b   Cabanillas, Maria E ^a   Caramella, Caroline ^b   Anderson, Pete ^a   Al Ghuzlan, Abir ^b   Waguespack, Steven G ^a   Deandreis, Desirée ^b   Baudin, Eric ^b   Jimenez, Camilo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; CARVEDILOL; CELIPROLOL; CYCLOPHOSPHAMIDE; DOXAZOSIN; FLUORODEOXYGLUCOSE F 18; IRBESARTAN; METIROSINE; METOPROLOL; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL; RAMIPRIL; RAPAMYCIN; SUNITINIB; TEMOZOLOMIDE; TERAZOSIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BONE METASTASIS; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INTENTION TO TREAT ANALYSIS; LUNG EDEMA; MALE; MOUTH PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SOFT TISSUE; SYMPATHETIC PARAGANGLIOMA; TUMOR VOLUME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84868621823     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2356     Document Type: Article

References (35)

1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT 1983 Occurence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58:802-804 (Pubitemid 14205531)
2. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C 2011 Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96:717-725
3. DeLellis RA Lloyd RV, Heitz PU, Eng C 2004 Pathology and genetics: tumours of endocrine organs (IARC WHO Classification of Tumours). Lyon, France: IARC Press
4. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C 2012 Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 44:390-399
5. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H 1990 Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21:277-282 (Pubitemid 20081227)
6. Favier J, Plouin PF, Corvol P, Gasc JM 2002 Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161:1235-1246
7. Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC, Duh QY 2002 VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132:1056-1063, discussion 1063
8. Salmenkivi K, Heikkilä P, Liu J, Haglund C, Arola J 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 111:458-464 (Pubitemid 36735003)
9. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P 2009 Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27:4162-4168
10. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP 2005 Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812-8818 (Pubitemid 46211527)
11. Santarpia L, Habra MA, Jiménez C 2009 Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res 41:680-686
12. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896 (Pubitemid 350002890)
13. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG 2009 Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94:386-391
14. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ 2009 Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 27:460-463
15. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ 2009 Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94:5-9
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
18. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, Kim YR, Park TS, Ahn JH, Lee DH, Kim TW, Lee JS 2009 Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 39:327-331
19. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nosé V, Li C, Stiles CD 2005 A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72-80
20. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER 2006 Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91:4593-4598 (Pubitemid 44833443)
21. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C 2010 A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 95:2023-2037
22. Timmers HJ, Pacak K, Bertherat J, Lenders JW, Duet M, Eisenhofer G, Stratakis CA, Niccoli-Sire P, Tran BH, Burnichon N, Gimenez-Roqueplo AP 2008 Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin Endocrinol (Oxf) 68:561-566 (Pubitemid 351388709)
23. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8:155-167 (Pubitemid 41132744)
24. Herrmann E, Bierer S, Wülfing C 2010 Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 28:303-309
25. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB 2009 Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41:697-702
26. Dancey JE 2006 Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5:1065-1073 (Pubitemid 44773684)
27. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H 2006 The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5:2522-2530 (Pubitemid 44650916)
28. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB 2007 The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13(2 Pt 2):758s-763s
29. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S 2009 In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11:426-435
30. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92:3822-3828 (Pubitemid 47607629)
31. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ 2012 Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118:1868-1876
32. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ 2011 Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773
33. Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF 2011 Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol 60:344-349
34. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF 2012 Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 44:385-389
35. Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP 2011 Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20:3974-3985